4 results match your criteria: "North Shore-LIJ Health System at Lenox Hill Hospital[Affiliation]"
Management of anticoagulants in the periprocedural period for patients with cancer.
J Natl Compr Canc Netw
December 2014
From North Shore-LIJ Health System at Lenox Hill Hospital and Hofstra North Shore-LIJ School of Medicine, New York, New York. From North Shore-LIJ Health System at Lenox Hill Hospital and Hofstra North Shore-LIJ School of Medicine, New York, New York.
Patients with cancer undergo surgeries and procedures for various purposes, including prophylaxis, diagnosis, staging, cure, debulking, palliation, and reconstruction. The diagnosis of cancer itself, along with the well-established complication of venous thromboembolism (VTE), places these patients at risk for perioperative thromboembolism. It is also well-established that continuing patients on oral anticoagulation therapy during the periprocedural period is associated with an increased risk of bleeding.
View Article and Find Full Text PDFExternal validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR).
Thromb Haemost
October 2014
Alex C Spyropoulos, MD, FACP, FCCP, FRCPC, Director - Anticoagulation Services and Clinical Thrombosis, North Shore-LIJ Health System at Lenox Hill Hospital, Professor of Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, New York, USA, Tel.: +1 212 434 6776, Fax: +1 212 434 6781, E-mail:
Venous thromboembolic (VTE) risk assessment remains an important issue in hospitalised, acutely-ill medical patients, and several VTE risk assessment models (RAM) have been proposed. The purpose of this large retrospective cohort study was to externally validate the IMPROVE RAM using a large database of three acute care hospitals. We studied 41,486 hospitalisations (28,744 unique patients) with 1,240 VTE hospitalisations (1,135 unique patients) in the VTE cohort and 40,246 VTE-free hospitalisations (27,609 unique patients) in the control cohort.
View Article and Find Full Text PDFVenous thromboembolism risk in patients with inflammatory bowel disease: defining the benefits of pharmacologic prophylaxis.
Clin Gastroenterol Hepatol
September 2014
Anticoagulation and Clinical Thrombosis Services, North Shore-LIJ Health System at Lenox Hill Hospital, New York, New York.
Venous thromboembolism management: where do novel anticoagulants fit?
Curr Med Res Opin
July 2013
North Shore/LIJ Health System at Lenox Hill Hospital, Hofstra-North Shore/LIJ School of Medicine, NY, NY, USA.
Objective: To review novel oral anticoagulant (NOAC) trials in the treatment of venous thromboembolism (VTE) and the possible use of risk-stratification tools to guide their use in practice.
Scope: MEDLINE and Cochrane databases were searched to identify relevant journal articles published from January 1982 to February 2013. Additional references were obtained from articles extracted during the database search.